Securities Code: 300357
Securities Abbreviation: I-Mab Biopharma
Announcement No.: 2026-02
Zhejiang I-Mab Biopharma Co., Ltd.
Announcement on Receiving Acceptance Notice for Cat Dander Allergen Oral Lyophilized Powder Clinical Trial Application
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Recently, Zhejiang I-Mab Biopharma Co., Ltd. (hereinafter referred to as the "Company") received an "Acceptance Notice" issued by the National Medical Products Administration. The clinical trial application for "Cat Dander Allergen Oral Lyophilized Powder" (hereinafter referred to as "this product") submitted by the Company has been formally accepted. The relevant content is hereby announced as follows:
I. Basic Information
Product Name: Cat Dander Allergen Oral Lyophilized Powder
Registration Category: Class 1 therapeutic biological product
Application Matter: Clinical trial for domestic production drug registration
Dosage Form: Lyophilized powder
Indication: As a specific immunotherapy, for adult patients with allergic rhinitis (with or without allergic conjunctivitis, allergic asthma) related to cat dander sensitization.
Drug Registration Applicant: Zhejiang I-Mab Biopharma Co., Ltd.